Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Oncology Research and Treatment

Guidelines for Authors

Types of Papers and Allotted Number of Pages
Conflicts of Interest
Ethical and Legal Prerequisites
Plagiarism Policy
Digital Object Identifier (DOI)
Supplementary Material
Self-Archiving/Green Open Access, Author's ChoiceTM,
   Funding Organizations (NIH etc.)

Page Charges
Edited Articles for Correction


'Oncology Research and Treatment' is a peer-reviewed journal intended to provide a forum for presentation of all aspects of oncology, including reviews and original articles from hematology and medical oncology, surgical, gynecological and urological oncology, radiation therapy as well as clinical-experimental oncology. Contributions to pediatric, ENT and dermatological oncology, pathology, biometry, epidemiology, prevention, early diagnosis and psychological care will also be considered.

Oncology Research and Treatment does not accept manuscripts reporting preclinical basic research based solely on in vitro data. Moreover, results from animal systems are only acceptable with a strong translational impact, i.e. if clinical (diagnostic or therapeutic) applications can be expected in the near future.

Manuscripts must be submitted online.

Should you have any problems with electronic submission please contact the Editorial Office:

Dr. Steffi Hentzelt
Editorial Office 'Oncology Research and Treatment'
S. Karger Verlag für Medizin und Naturwissenschaften GmbH
P.O. Box
79095 Freiburg (Germany)
Tel. +49 761 45 20 725
Fax +49 761 45 20 714


All contributions must be written in English (American or British spelling and grammar).

Types of Papers and Allotted Number of Pages

Please print the manuscript 1 1/2-spaced with 3-cm margins (left and right). Use only one format (normal) for the document.

The text should be limited to the following number of pages:
Printed pages Equals approx. characters*
Review Article, Original Article 5 30,000
Novel Insights from Clinical Practice (formerly Case Reports) 3 18,000
Ongoing Clinical Trial, Oncological Education, Clinical Information 4 24,000
Letter to the Editor 1 6,000
Others 2 12,000

* including title page, summary, main text, illustrations, tables, and references. Each table or figure counts for 1,500 characters. Each additional complete or partial page to print will be charged to the author.

Novel Insights from Clinical Practice (formerly Case Reports): The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. The most important aspect of the presentation is that it should provide a new perspective on a recognized clinical scenario or may represent an entirely new clinical condition. Highlighted boxes containing one or two bullet points on Established facts (what is already known) and Novel insights (what new information has been gained) are required and should be placed on the first page of the report. These should highlight the novelty of the clinical observation. The manuscript should be presented with an abstract (max. 200 words), followed by introduction, case report, and discussion.


Acceptance of a manuscript is based on the evaluation by several reviewers (peer review).

Manuscripts are received with the explicit understanding that the article has not been published, neither wholly nor in part, has not been submitted for publication anywhere else and is not under consideration by any other journal. Submission of an article for publication implies that the authors are the owners of the copyright and that the article does not infringe any existing third party rights, including copyright and intellectual property rights.

It is the authors' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Once the manuscript is accepted for publication, the authors grant S. Karger Publishers a license to publish and reproduce the article in either its present form or revised version for any possible use and identify themselves as the original publishers. This right extends also to associated companies. The publishing rights are worldwide rights and are not time-limited. They include the right to publish the text in printed format as well as electronic online and offline media or databases of any kind. Accepted papers, in whole or in part, may not be translated into other languages, or reproduced by any mechanical or electronic means (including photocopying, recording and microcopying), or stored in a retrieval system without the written consent of the publisher.

License Agreement (PDF)

The publisher reserves the right to edit the manuscript and decide on the layout.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research, and all authors must disclose any possible conflicts of interest. Disclosure statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925-926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.

Experiments involving animals demand consent as well and must meet the requirements of German laws for the protection of animals in their current version. A reference to this approval must be included in the manuscript. Articles from countries other than Germany must include a comparable note.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation.
If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).


Title page: The first page of each paper should indicate the title and a short title for use as running head.

Authors' affiliations and address of correspondence: Each author's full name, followed by their affiliation (hospital, institute etc. where the work was conducted) and the exact postal address of the corresponding author complete with postal code must be given. Please also supply phone and fax numbers, as well as e-mail address.

Keywords: For indexing purposes, a list of 3-5 keywords is essential. Whenever possible, use keywords such as found in the Medical Subject Headings List (MeSH) of Index Medicus (see www.nlm.nih.gov).

Summary: The summary must not exceed 200 words. Summaries of Original Articles and Novel Insights from Clinical Practice should be structured as follows: Background (or Introduction), Patients and Methods (or Material and Methods), Results, Conclusion.

Footnotes: Footnotes should be used only for tables.

Registered Trade Names: When first mentioned, registered trade names must be marked with the superscript registration symbol® or ™. It is the sole responsibility of the author to ensure that this rule is followed properly.

Tables and Illustrations: Tables are part of the text and should be placed at the end of the text file. Illustration data must be stored as separate files. The number of figures and tables should be limited and aim to illustrate the text. Figures are listed in the text as (fig. 1), tables as (table 1). Data already mentioned in the text need not be repeated in a table. Accordingly, numbers used in tables need not be repeated in the text.

Illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600–800 dpi.

Color illustrations are reproduced at the author's expense. Each one is charged to the author at EUR 380.00 (incl. VAT) as contribution to the additional reproduction and color printing costs.


The list of references should include only the publications cited in the text. The list should not exceed 60 references for reviews.

References must be numbered sequentially in the order cited in the text. In the text identify references by Arabic numerals [in square brackets].

In each reference all authors should be named; the abbreviation 'et al.' is to be avoided.

It is recommended to quote only articles already published or accepted for publication. Please avoid 'in preparation' or 'personal communication'.

Authors are responsible for the accuracy and completeness of their references and for correct citation.

Journal titles should be abbreviated according to the Index Medicus system (www.nlm.nih.gov). If a reference manager is used, the style "Pharmacology" or "Nephron" should be chosen.

Examples for references:

Papers published in periodicals:
Wick, Küker W: Brain edema in neurooncology: radiological assessment and management. Onkologie 2004;27:261–266.

Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Papers published in electronic format:
Black CA: Delayed type hypersensitivity: Current theories with a historic perspective. Dermatol Online J 1999;5:7. http://dermatology.dclib.org/DOJvol5num1.

Edited books:
Itskovitz-Eldor J, Amit M: Human embryonic stem cells; in Blazer S, Zimmer EZ (eds): The Embryo: Scientific Discovery and Medical Ethics. Basel, Karger, 2005, pp 74–90.

Büchler MW, Uhl W, Malfertheiner P, Sarr MG: Diseases of the Pancreas. Basel, Karger, 2004.

Reference Management Software:Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

A DOI number will be available as a unique identifier on the title page of each article. DOIs are useful for identifying and citing articles published online without volume or issue information (for more information, see www.doi.org).

Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of EUR 298.00 (incl. VAT) for supplementary material.

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

  • Be used for noncommercial purposes only
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf [see Funding Organizations (NIH etc.)].

For self-archiving Author's ChoiceTM (Gold Open Access) articles, see Author's ChoiceTM.

Author's ChoiceTM

Karger’s Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of EUR 2,130.00 (incl. VAT), which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:

  • Follow the terms of the relevant Creative Commons license
  • Be linked to the final version on www.karger.com
  • Include the following statement:

‘The final, published version of this article is available at http://www.karger.com/?doi=[insert DOI number].’

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's ChoiceTM, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC.
Authors should include information on their grant in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers that do not exceed the allotted size (cf. types of papers).

Each additional complete or partial page is charged to the author at EUR 510.00 (incl. VAT).

Edited Articles for Correction

Unless indicated otherwise, edited articles are sent to the corresponding author and should be returned with the least possible delay. Changes made in the articles, other than the correction of editing errors, are charged to the author. No page proofs are supplied.


Order forms and a price list are sent with the edited articles. Orders submitted after the issue is printed are subject to considerably higher prices.